预约演示
更新于：2024-12-26
Avatrombopag Maleate
马来酸阿伐曲泊帕
更新于：2024-12-26
概要
基本信息
药物类型 小分子化药 |
别名 avatrombopag、Avatrombopag maleate (JAN/USAN)、AKR-501 + [13] |
作用机制 TPO receptor激动剂(血小板生成素受体激动剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2018-05-21), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C33H38Cl2N6O7S2 |
InChIKeyMISPBGHDNZYFNM-BTJKTKAUSA-N |
CAS号677007-74-8 |
关联
102
项与 马来酸阿伐曲泊帕 相关的临床试验CTRI/2024/08/072877
An Open Label Balanced Randomized Single Dose Two Treatment Three Sequence Three Period Partial Replicate Reference Scaled Average Oral Bioequivalence Study of Avatrombopag Maleate 20 Mg Tablets Manufactured by Bdr Pharmaceuticals Internationals Pvt Ltd India with Doptelet (avatrombopag) 20 mg Tablets Manufactured By Swedish Orphan Biovitrum Ab Publ Stockholm Sweden Se 11276 In Healthy Adult Human Subjects Under Fed Conditions - Nil
NCT06202625
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haploidentical Hematopoietic Stem Cell Transplantation: Prospective, Multi-center, Double-blinded, Randomized Placebo-controlled Study
CTR20241386
马来酸阿伐曲泊帕片在健康受试者中的单剂量、随机、开放、空腹和餐后生物等效性研究
100 项与 马来酸阿伐曲泊帕 相关的临床结果
登录后查看更多信息
100 项与 马来酸阿伐曲泊帕 相关的转化医学
登录后查看更多信息
100 项与 马来酸阿伐曲泊帕 相关的专利（医药）
登录后查看更多信息
149
项与 马来酸阿伐曲泊帕 相关的文献（医药）2024-12-31ANNALS OF MEDICINE
Cyclosporine plus avatrombopag versus cyclosporine monotherapy for first-line treatment of elderly patients with transfusion-dependent non-severe aplastic anemia: a single center retrospective study
Article
作者: Chen, Miao ; Yang, Chen ; Zhang, Zhuxin ; Hu, Qinglin ; Han, Bing ; Wang, Leyu
BACKGROUND:
Elderly patients with transfusion-dependent non-severe aplastic anemia (TD-NSAA) face limited treatment options owing to transplantation incompatibility and safety concerns.
METHODS:
Data from older patients (≥60 years) newly diagnosed with TD-NSAA and had been treated with either avatrombopag (AVA) + cyclosporine (CsA) or CsA monotherapy at our center were retrospectively collected.
RESULTS:
In total, 52 patients were enrolled, with 26 receiving AVA + CsA and 26 receiving CsA monotherapy. The overall response (OR) rate was higher in the AVA + CsA group than in the CsA group at the 1st, 2nd, 3rd, 6th months, and at the end of the follow-up (all p < 0.05). The complete response (CR) rate was higher in the AVA + CsA group than in the CsA group at the 6th month and at the end of follow-up (p = 0.017 and 0.039). Patients receiving AVA + CsA had a shorter time to achieve the first response (p = 0.008) and CR (p = 0.010) than those receiving CsA monotherapy. Furthermore, patients receiving AVA + CsA exhibited a higher rate of platelet transfusion independence at the 3rd (p = 0.041), 6th (p = 0.008) months, and likewise at the end of the follow-up (p = 0.097).
CONCLUSIONS:
The addition of AVA to CsA can significantly improve the OR or CR rate and platelet levels with acceptable side effects in elderly patients, which implies that the combination is a viable alternative for elderly patients with TD-NSAA.
2024-12-01BRITISH JOURNAL OF HAEMATOLOGY
Real‐world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag/hetrombopag
Article
作者: Gu, Cheng‐Yuan ; Liu, Xiao‐fan ; Yu, Zi‐Qiang ; Li, Yun ; Tian, Hong ; Yin, Jie ; Dai, Jia‐wen ; Zhou, Lu ; Kong, Dan‐Qing
Summary:
Due to the limited real‐world research on the application of avatrombopag (AVA) for immune thrombocytopenia (ITP) in China, we evaluated the effectiveness and safety of AVA in clinical practice. We included 121 adult ITP patients treated with AVA across three medical centres. Based on the reasons for choosing AVA, these patients were divided into eltrombopag (ELT)/hetrombopag (HET) intolerance group (IG), and ELT/HET unresponsive group (UG). Compared with UG, more patients in IG had a history of liver disease and received fewer treatments before AVA. Amongst all patients, 83% had platelet response (≥30 × 109/L) after AVA and 62% achieved complete response (≥100 × 109/L, CR). Sixty‐two percent in IG and 56% in UG were able to discontinue more than one concomitant ITP medication. A total of 17 patients underwent multiple switches of thrombopoietin receptor agonists (TPO‐RAs), resulting in an 88% platelet response rate. Sixty‐three patients discontinued AVA, 27% were due to unaffordability. AVA was well tolerated in most patients. In the ITP population, AVA proved effective and safe, particularly in patients intolerant or unresponsive to ELT/HET. Patients benefited from TPO‐RAs switches, particularly those undergoing multiple switches. However, many patients struggled with the long‐term financial burden of AVA.
2024-12-01AMERICAN JOURNAL OF HEMATOLOGY
Avatrombopag in immune thrombocytopenia: A real‐world study of the Spanish ITP Group (GEPTI)
Article
作者: Arquero, Teresa ; Caparrós‐Miranda, Isabel ; de‐Laiglesia, Almudena ; Moreno‐Carbonell, Marta ; Llácer, María‐José ; Pedrote‐Amador, Begoña ; Gil‐Fernández, Juan‐José ; Canet, Marta ; Chica‐Gullón, Esther ; Cuesta, Amalia ; Zafra‐Torres, Denis ; Jarque‐Ramos, Isidro ; Lasa‐Eguialde, Maialen ; Lakhwani, Sunil ; Bernat, Silvia ; Mingot‐Castellano, María‐Eva ; Sánchez‐González, Blanca ; Bastida, José‐María ; Menor‐Gómez, María ; García‐Donas, Gloria ; Díaz‐López, Marta ; Lorenzo‐Vizcaya, Álvaro ; Caballero‐Navarro, Gonzalo ; Ortúzar‐Pasalodos, Ariana ; Pascual‐Izquierdo, Cristina ; Alvarellos, Montserrat ; Martínez‐Carballeira, Daniel ; González‐Gascón‐y‐Marín, Isabel‐Teresa ; Moreno‐Beltrán, María‐Esperanza ; Álvarez‐Román, María‐Teresa ; López‐Ansoar, Elsa ; Revilla‐Calvo, Nuria ; Aguirre, María‐Aránzazu ; Monsalvo‐Saornil, Silvia ; Jiménez‐Bárcenas, Reyes ; Canaro‐Hirnyk, Mariana‐Isabel
Abstract:
Avatrombopag is the newest thrombopoietin receptor agonist (TPO‐RA) approved to treat immune thrombocytopenia (ITP). Real‐world evidence regarding effectiveness/safety is limited. The Spanish ITP Group (GEPTI) performed a retrospective study with patients starting avatrombopag for the first time. A total of 268 ITP patients were recruited. The median (interquartile range [IQR]) follow‐up time was 47.5 (30.4–58.9) weeks. Among the 193 patients with baseline platelet counts <50 × 109/L, 174 (90.1%) of them achieved response (PC ≥50 × 109/L), and 113 (87.6%) of the 129 who persisted on avatrombopag at last visit had platelet levels above such threshold. Results were similar when only those patients switching to avatrombopag due to previous treatment failure were considered (n = 104). Patients reached response in 13 (7–21) days. Among patients with baseline levels ≥50 × 109/L, 73/75 (97.3%) reported response, which was maintained by 53 (94.6%) of the 56 who continued on avatrombopag at the end of the study. Loss‐of‐response was always <10%. ITP duration did not influence response. Approximately 79% (34/43) of heavily pretreated (≥4 lines) patients with baseline platelet counts <50 × 109/L switching after previous failure achieved PC ≥50 × 109/L. Previous use of eltrombopag and/or romiplostim did not influence response, regardless of whether previous TPO‐RA(s) succeeded or failed. Avatrombopag allowed dose‐reduction/suspension of corticosteroids in 40/50 (80.0%) patients with baseline platelet counts <50 × 109/L. Overall, 40/268 (14.9%) thrombocytosis and 12/268 (4.5%) thromboembolic events were reported. Our real‐world cohort supports the use of avatrombopag to manage ITP, regardless of disease severity and treatment history.
100 项与 马来酸阿伐曲泊帕 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肝病 | 加拿大 | 2023-11-03 | |
| 免疫性血小板减少症 | 欧盟 | 2019-06-20 | |
| 免疫性血小板减少症 | 冰岛 | 2019-06-20 | |
| 免疫性血小板减少症 | 列支敦士登 | 2019-06-20 | |
| 免疫性血小板减少症 | 挪威 | 2019-06-20 | |
| 血小板减少症 | 美国 | 2018-05-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性血小板减少症 | 临床3期 | 中国 | 2021-03-02 | |
| 原发性血小板减少症 | 临床3期 | 中国 | 2021-03-02 | |
| 原发性血小板减少症 | 临床3期 | 中国 | 2021-03-02 | |
| 慢性特发性血小板减少性紫癜 | 临床3期 | 美国 | 2012-03-26 | |
| 慢性血小板减少症 | 临床3期 | 澳大利亚 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 比利时 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 保加利亚 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 捷克 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 荷兰 | 2012-02-16 | |
| 慢性血小板减少症 | 临床3期 | 新西兰 | 2012-02-16 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 顧遞鑰選艱醖淵願製夢(網遞網顧築夢糧簾餘憲) = A total of 49 adverse events (AEs) were reported in 29/190 patients (15.3%) in the FAS, with 15 AEs in ten patients (5.3%) considered AVA-related. Two patients discontinued AVA treatment due to AEs, which included abdominal pain and fatigue. 鏇顧網選獵齋繭構築壓 (鏇鹹範製網製積蓋蓋繭 ) | - | 2024-12-09 | |||
N/A | - | 窪齋觸遞廠壓選鹹築餘(襯餘餘壓選醖廠膚遞顧) = 憲觸餘獵廠艱壓鏇蓋鬱 襯繭夢醖遞願鏇憲鹹範 (壓憲餘簾簾膚構顧膚齋 ) 更多 | - | 2024-12-08 | |||
Romiplostim | 窪齋觸遞廠壓選鹹築餘(襯餘餘壓選醖廠膚遞顧) = 獵網膚鏇鹹顧艱鹹鹹鑰 襯繭夢醖遞願鏇憲鹹範 (壓憲餘簾簾膚構顧膚齋 ) 更多 | ||||||
N/A | 47 | 糧夢鹹製觸製艱築憲築(鬱簾構窪鹹壓簾蓋窪壓) = 製鏇觸窪選獵壓艱築繭 憲鏇顧蓋鑰糧夢糧積製 (鏇鏇窪餘選艱衊艱蓋窪 ) 更多 | 积极 | 2024-12-08 | |||
N/A | - | 窪膚鬱糧夢簾糧簾築壓(襯遞簾鹹觸積夢鏇蓋膚) = 窪構製願蓋構網窪願製 鹹膚醖遞襯壓鏇廠鹽夢 (壓觸鑰蓋齋選蓋觸簾範 ) 更多 | - | 2024-12-08 | |||
Romiplostim | 窪膚鬱糧夢簾糧簾築壓(襯遞簾鹹觸積夢鏇蓋膚) = 簾範蓋鹹繭膚網簾選膚 鹹膚醖遞襯壓鏇廠鹽夢 (壓觸鑰蓋齋選蓋觸簾範 ) 更多 | ||||||
N/A | - | 壓廠顧觸遞繭鏇膚遞蓋(糧顧鑰廠淵膚簾壓糧壓) = 鏇製鹽鏇鬱夢遞衊醖鹽 獵憲齋鬱憲鬱範齋衊窪 (鏇夢範網艱鹹範淵齋艱 ) | - | 2024-12-07 | |||
临床4期 | - | 52 | 糧廠糧遞膚餘醖鏇範餘(壓簾艱衊繭網鏇顧觸淵) = 積廠蓋廠觸壓選願範築 鏇網夢廠餘選齋醖積醖 (廠選衊膚製廠壓簾鬱遞 ) | 积极 | 2024-12-07 | ||
AVESPA (EHA2024) 人工标引  | N/A | 240 | 範選範艱構憲構鹹範觸(壓鏇壓範淵顧積淵鏇繭) = 製觸膚製衊網鹹鹹築網 醖壓築餘網構鏇選鬱獵 (襯衊觸蓋壓繭鹹襯艱糧 ) 更多 | 积极 | 2024-05-14 | ||
(severe ITP) | 範選範艱構憲構鹹範觸(壓鏇壓範淵顧積淵鏇繭) = 夢觸憲鑰選製獵廠積蓋 醖壓築餘網構鏇選鬱獵 (襯衊觸蓋壓繭鹹襯艱糧 ) 更多 | ||||||
EHA2024 人工标引 | N/A | 20 | 遞鏇簾繭淵築醖窪蓋顧(鬱簾繭鹽壓鹹積遞鏇餘) = 壓壓鏇廠簾獵淵製鏇糧 簾鏇糧鏇鏇繭膚衊鑰鑰 (構獵窪艱範蓋簾範膚夢, 34 ~ 47) 更多 | 积极 | 2024-05-14 | ||
临床3期 | 75 | 襯鹽遞簾獵網製製選鑰(鏇窪蓋餘觸醖餘艱鑰範) = 鬱餘壓廠窪鹹鹽糧鹽網 襯範餘顧醖廠憲製製網 (夢繭鏇膚構築願壓鏇襯 ) 达到 更多 | 积极 | 2024-05-14 | |||
临床4期 | 47 | 積遞鏇選願襯鹹壓醖獵(憲壓鑰糧淵蓋願廠範壓) = 積鬱膚壓鹽憲壓繭選鹽 獵鹽蓋遞膚鹽餘廠獵鹽 (構構醖積憲蓋觸壓簾網 ) 更多 | 积极 | 2024-05-14 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用